KR20140121477A - Tank 및 parp 저해체로서의 테트라히드로-퀴나졸리논 - Google Patents

Tank 및 parp 저해체로서의 테트라히드로-퀴나졸리논 Download PDF

Info

Publication number
KR20140121477A
KR20140121477A KR1020147024967A KR20147024967A KR20140121477A KR 20140121477 A KR20140121477 A KR 20140121477A KR 1020147024967 A KR1020147024967 A KR 1020147024967A KR 20147024967 A KR20147024967 A KR 20147024967A KR 20140121477 A KR20140121477 A KR 20140121477A
Authority
KR
South Korea
Prior art keywords
het
pharmaceutically acceptable
salts
formula
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147024967A
Other languages
English (en)
Korean (ko)
Inventor
한스-페터 부흐슈탈러
크리슈티나 에스다르
비르기타 로이트너
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140121477(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20140121477A publication Critical patent/KR20140121477A/ko
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020147024967A 2012-02-09 2013-01-14 Tank 및 parp 저해체로서의 테트라히드로-퀴나졸리논 Ceased KR20140121477A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12000841.2 2012-02-09
EP12000841 2012-02-09
PCT/EP2013/000078 WO2013117288A1 (en) 2012-02-09 2013-01-14 Tetrahydro-quinazolinone derivatives as tank and parp inhibitors

Publications (1)

Publication Number Publication Date
KR20140121477A true KR20140121477A (ko) 2014-10-15

Family

ID=47628092

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147024967A Ceased KR20140121477A (ko) 2012-02-09 2013-01-14 Tank 및 parp 저해체로서의 테트라히드로-퀴나졸리논

Country Status (31)

Country Link
US (1) US9339503B2 (https=)
EP (1) EP2812323B1 (https=)
JP (1) JP6116592B2 (https=)
KR (1) KR20140121477A (https=)
CN (1) CN104093714B (https=)
AR (1) AR089944A1 (https=)
AU (1) AU2013218357B2 (https=)
BR (1) BR112014019357A8 (https=)
CA (1) CA2863991C (https=)
CL (1) CL2014002097A1 (https=)
CO (1) CO7020919A2 (https=)
DK (1) DK2812323T3 (https=)
EA (1) EA026611B1 (https=)
EC (1) ECSP14017586A (https=)
ES (1) ES2579980T3 (https=)
HR (1) HRP20160735T1 (https=)
HU (1) HUE029717T2 (https=)
IL (1) IL233984A (https=)
MX (1) MX349736B (https=)
NZ (1) NZ630170A (https=)
PE (1) PE20141823A1 (https=)
PH (1) PH12014501581A1 (https=)
PL (1) PL2812323T3 (https=)
PT (1) PT2812323T (https=)
RS (1) RS55377B1 (https=)
SG (1) SG11201404654SA (https=)
SI (1) SI2812323T1 (https=)
TW (1) TWI572593B (https=)
UA (1) UA116627C2 (https=)
WO (1) WO2013117288A1 (https=)
ZA (1) ZA201406579B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190044054A (ko) * 2016-06-30 2019-04-29 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 신규 화합물 또는 그의 약학적으로 허용가능한 염

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP2890696A1 (en) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
HUE030613T2 (en) 2012-12-31 2017-05-29 Cadila Healthcare Ltd Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
BR112016008994A2 (pt) * 2013-11-07 2017-09-19 Lilly Co Eli Compostos de pirido[2,3-d]pirimidin-4-ona como inibidores de tanquirase
US10316025B2 (en) 2015-06-03 2019-06-11 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN108727302A (zh) * 2017-10-23 2018-11-02 科迈化工股份有限公司 一种环保型n-叔丁基-2-苯并噻唑次磺酰胺(ns)合成工艺
EP3733186B1 (en) 2017-12-27 2024-12-04 Japanese Foundation For Cancer Research Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor
JP7369968B2 (ja) * 2017-12-27 2023-10-27 公益財団法人がん研究会 抗がん剤
AU2019320945C1 (en) 2018-08-16 2021-09-30 F. Hoffmann-La Roche Ag Fused ring compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
AUPR975601A0 (en) * 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
ATE540936T1 (de) * 2004-06-30 2012-01-15 Janssen Pharmaceutica Nv Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ES2359931T3 (es) 2005-03-11 2011-05-30 Merck Patent Gmbh Tetrahidro- y dihidroquinazolinonas.
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2011111880A1 (ko) * 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190044054A (ko) * 2016-06-30 2019-04-29 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 신규 화합물 또는 그의 약학적으로 허용가능한 염

Also Published As

Publication number Publication date
TW201336828A (zh) 2013-09-16
SI2812323T1 (sl) 2016-08-31
NZ630170A (en) 2016-03-31
CA2863991C (en) 2020-08-11
CN104093714B (zh) 2016-08-24
SG11201404654SA (en) 2014-09-26
CA2863991A1 (en) 2013-08-15
HUE029717T2 (en) 2017-03-28
AU2013218357A1 (en) 2014-09-25
EP2812323A1 (en) 2014-12-17
ECSP14017586A (es) 2015-09-30
US9339503B2 (en) 2016-05-17
EA026611B1 (ru) 2017-04-28
TWI572593B (zh) 2017-03-01
DK2812323T3 (en) 2016-05-09
HK1202551A1 (zh) 2015-10-02
WO2013117288A8 (en) 2014-07-31
PL2812323T3 (pl) 2016-09-30
PH12014501581B1 (en) 2014-10-08
IL233984A (en) 2017-09-28
MX349736B (es) 2017-08-10
UA116627C2 (uk) 2018-04-25
CO7020919A2 (es) 2014-08-11
US20150025071A1 (en) 2015-01-22
JP6116592B2 (ja) 2017-04-19
PH12014501581A1 (en) 2014-10-08
BR112014019357A2 (https=) 2017-06-20
ZA201406579B (en) 2015-12-23
AU2013218357A8 (en) 2015-01-22
EP2812323B1 (en) 2016-04-06
ES2579980T3 (es) 2016-08-18
AR089944A1 (es) 2014-10-01
CL2014002097A1 (es) 2014-11-07
EA201400879A1 (ru) 2015-01-30
HRP20160735T1 (hr) 2016-07-29
PE20141823A1 (es) 2014-11-29
RS55377B1 (sr) 2017-03-31
CN104093714A (zh) 2014-10-08
AU2013218357B2 (en) 2017-01-05
WO2013117288A1 (en) 2013-08-15
PT2812323T (pt) 2016-07-13
BR112014019357A8 (pt) 2017-07-11
MX2014009491A (es) 2014-08-29
JP2015506965A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
JP6333450B2 (ja) (アザ−)イソキノリノン誘導体
AU2013324681B2 (en) Quinazolinone derivatives as PARP inhibitors
KR20140121477A (ko) Tank 및 parp 저해체로서의 테트라히드로-퀴나졸리논
AU2013242492B2 (en) Bicyclic pyrazinone derivatives
JP6097820B2 (ja) ピロロトリアジノン誘導体
KR20150061644A (ko) 지방산 신타아제 저해제로서의 히드로피롤로피롤 유도체
KR20160023854A (ko) 프탈라진 유도체
HK1202551B (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
HK1209106B (en) (aza-)isoquinolinone derivatives
HK1210777B (en) Quinazolinone derivatives as parp inhibitors
HK1205740B (en) Pyrrolotriazinone derivatives
HK1203961B (en) Bicyclic pyrazinone derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140904

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180112

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190527

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190813

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190527

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I